OncoMatch/Clinical Trials/NCT06447597
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
Is NCT06447597 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies B007 for generalized myasthenia gravis.
Phase 2/3RecruitingShanghai Jiaolian Drug Research and Development Co., LtdNCT06447597Data as of May 2026
Treatment: B007 — The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with generalized myasthenia gravis.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: CHRNA1 antibody positive
Serum AchR(Acetylcholine receptor)-Ab ... was positive during screening
Required: MUSK antibody positive
Serum ... MUSK-Ab was positive during screening
Disease stage
Excluded: Stage MGFA I, MGFA V
Subjects with MGFA I and V type [excluded]
Prior therapy
Min 1 prior line
Must have received: standard of care for generalized myasthenia gravis
subjects received at least one gMG stable dose of SoC, and maintain a stable dose throughout the test
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify